Lyudmila Bazhenova, MD, Discusses the Outcomes With Immunotherapy in Wild-Type vs EGFR Exon 20 NSCLC
October 24th 2021CancerNetwork® sat down with Lyudmilia Bazhenova, MD, at the 2021 World Conference on Lung Cancer to discuss differences in outcomes with immunotherapy agents in patients with wild-type and EGFR exon 20 insertion–positive non–small cell lung cancer.
Presentation: Benefits and Limitations of RWE: Lessons From EGFR Mutation-Positive NSCLC
October 21st 2021Dr. Lyudmila Bazhenova presents a recently published article by Nazha B, et al., “Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer.”
Luciano Costa, MD, PhD, Shares Key Takeaways From the MASTER Trial in Multiple Myeloma
October 19th 2021CancerNetwork® sat down with Luciano Costa, MD, PhD, at the 2021 International Myeloma Workshop to discuss the benefit of treatment with daratumumab, carfilzomib, lenalidomide, and dexamethasone and the population of patients with newly diagnosed myeloma who will best benefit from treatment.
Scott T. Tagawa, MD, MS, on Compelling ESMO Data for Metastatic Castration-Sensitive Prostate Cancer
October 18th 2021Scott Tagawa, MD, MS, detailed 2 presentations from ESMO’s presidential symposium that he thinks will have an impact on treating patients with metastatic castration-sensitive prostate cancer.